About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
SOHO Italy 1st School of Multiple Myeloma
Videos
Event
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of Daratumumab?
By
SOHO Italy 1st School of Multiple Myeloma
FEATURING
Claudio Cerchione
By
SOHO Italy 1st School of Multiple Myeloma
FEATURING
Claudio Cerchione
88 views
February 4, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Videos
20:07
SOHO Italy 1st School of Multiple Myeloma
Present Landscape of R/R MM: Post-Bortezomib, Post-Lenalidomide
Feat.
C. Cerchione
09:45
SOHO Italy 1st School of Multiple Myeloma
Near-Future Therapy Landscape of R/R MM at Second or Subsequent Rela…
Feat.
C. Cerchione
30:19
SOHO Italy 1st School of Multiple Myeloma
[PRIVATE] Present & Near Future of R/R MM: Post-Bortezomib, Post…
Feat.
C. Cerchione
13:49
SOHO Italy 1st School of Multiple Myeloma
MM & Extracellular Vesicles: Do MICA+ EVs Impair NKG2D-Mediated …
Feat.
E. Vulpis
27:26
SOHO Italy 1st School of Multiple Myeloma
Cell-Adhesion System Targeting in MM: How Does JAM-A Expression Corr…
Feat.
A. Solimando
22:20
SOHO Italy 1st School of Multiple Myeloma
Single-Cell Characterization of the BM Immune Microenvironment in MM…
Feat.
C. Botta
23:39
SOHO Italy 1st School of Multiple Myeloma
ASCT in MM in Novel Agents Era: Is Long-Term Disease Control and Sur…
Feat.
A. Olivieri
16:03
SOHO Italy 1st School of Multiple Myeloma
Primary Plasma Cell Leukemia Peru Experience: How Common Is PCL in M…
Feat.
J. Vasquez
19:12
SOHO Italy 1st School of Multiple Myeloma
1st/2nd Relapse in MM: Predictive Factors, EMD, Role of sFLC in MGUS…
Feat.
U. Markovic
16:38
SOHO Italy 1st School of Multiple Myeloma
Extracellular Vesicles in Myeloma: What Is Their Role in MGUS-to-MM …
Feat.
A. Reale
13:44
SOHO Italy 1st School of Multiple Myeloma
MRD Assessment Within the Bone Marrow of MM: Immunoglobulin Genes as…
Feat.
C. Terragna
22:16
SOHO Italy 1st School of Multiple Myeloma
Molecular Pathogenesis of MM: MGUS and SMM, Genomic Complexity of th…
Feat.
N. Bolli
18:23
SOHO Italy 1st School of Multiple Myeloma
Bone Marrow Fibroblasts in MM Progression and Tumor Cells Reprogramm…
Feat.
I. Saltarella
20:55
SOHO Italy 1st School of Multiple Myeloma
The Myeloma-Specific Tumor Suppressor FAM46C: How Does It Work &…
Feat.
E. Milan
08:20
SOHO Italy 1st School of Multiple Myeloma
1L LenDex Combo in Frail MM Patients: How Effective Is It? Is There …
Feat.
C. Bellofiore
13:41
SOHO Italy 1st School of Multiple Myeloma
NGS in ALL: Is INO Effective in MRD+ Patients Before HSCT? How Valua…
Feat.
G. Martinelli
16:57
SOHO Italy 1st School of Multiple Myeloma
Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of …
Feat.
C. Cerchione
26:05
SOHO Italy 1st School of Multiple Myeloma
Introducing Anti-CD38 in Daily Practice of MM: Updates on the GRIFFI…
Feat.
C. Cerchione
19:13
SOHO Italy 1st School of Multiple Myeloma
Daratumumab in MM Daily Practice: Is It Becoming the New Backbone?
Feat.
C. Cerchione
10:00
SOHO Italy 1st School of Multiple Myeloma
Bone Marrow CD8+ Tissue-Resident Memory T-Cells in MM: Can the Incre…
Feat.
M. Carlisi
13:19
SOHO Italy 1st School of Multiple Myeloma
European Experience in MM: What Are the Potential 1L Options for Tra…
Feat.
M. Mateos
10:48
SOHO Italy 1st School of Multiple Myeloma
Exploring Microenvironment of Multiple Myeloma: How Important Is It …
Feat.
A. Romano
09:25
SOHO Italy 1st School of Multiple Myeloma
2021 Update Combination Therapies in R/R MM: Which Options Are the M…
Feat.
F. Fazio
15:22
SOHO Italy 1st School of Multiple Myeloma
Dissecting Daratumumab Mechanisms of Resistance in MM: Identificatio…
Feat.
M. Claudio Da Via
09:34
SOHO Italy 1st School of Multiple Myeloma
Comparison of Different Imaging Techniques in MM: Whole-Body Compute…
Feat.
S. Grammatico
10:25
SOHO Italy 1st School of Multiple Myeloma
Combination Therapy in MM: Does Doxorubicin & ENPP1 Inhibitor Co…
Feat.
L. Cuollo
11:33
SOHO Italy 1st School of Multiple Myeloma
Allograft in MM: Is There a Role for AlloHSCT & Will Newer Drug …
Feat.
F. Vozella
14:02
SOHO Italy 1st School of Multiple Myeloma
2021 Update on R/R MM: Does the Addition of BCNU to Melphalan Improv…
Feat.
J. Thomas